Fortress Biotech: 3 Key Takeaways for Long-Term Investors
Clinical data showing Emrosi clearing skin in 30% of patients versus 12.8% for Oracea gives the rosacea franchise its clearest edge yet.
Full story
Read the full story at The Motley Fool ↗
Continue reading this story on The Motley Fool, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.
